Focus: Orion Pharma is a UK-based pharmaceutical company headquartered in Reading, specializing in small molecules and generics with a focus on neurology. The company's portfolio is heavily concentrated in Parkinson's disease treatments, particularly the STALEVO family of combination products.
Profile data last refreshed 8h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Orion Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship product representing 36% of company revenue; patent cliff imminent with no exclusive generic competition barrier.
Help build intelligence for Orion Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Orion Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest STALEVO strength; approaching loss of exclusivity with material revenue erosion expected.
Mid-tier STALEVO variant; vulnerable to generic competition upon patent expiration.
Lowest-strength STALEVO formulation; limited revenue but subject to same patent cliff exposure.
Monotherapy option for Parkinson's; approaching loss of exclusivity with modest revenue base.
Mid-range strength variant; minor contributor facing patent expiration risk.
Lowest-revenue STALEVO strength; smallest Part D footprint among portfolio variants.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo